CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PrazosinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug658 Convalescent plasma Wiki 0.18
drug2326 Standard of care Wiki 0.16
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D013313 Stress Disorders, Post-Traumatic NIH 0.14
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Noradrenergic Biomarkers in PTSD: Precision Medicine & Mechanisms

Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. There are a variety of treatment options for PTSD, including psychotherapy (talk therapy) options, as well as medications, such as the drug prazosin. Each of the treatment options available is effective at significantly reducing the symptoms of PTSD in some, but not all, individuals with PTSD. However, investigators are not yet able to predict in advance who is likely to respond to which of the available treatments. Neither are the investigators able to explain what changes in the brain after exposure to a traumatic stressors, and why it results in persistent symptoms of PTSD for some people, but not for others. In this study, the investigators are testing two things: First, is testing whether two simple, easy tests of how an individual's blood pressure changes with standing and how an individual's eye reacts to a pulse of light may be able to predict whether that person is likely to respond to the medication prazosin for PTSD. Second, is testing whether those who have been exposed to a traumatic stress show differences in how their body regulates the response to the stress-signal noradrenaline.

NCT03539614 Posttraumatic Stress Disorder Drug: Prazosin Drug: Placebo
MeSH:Stress Disorders, Post-Traumatic

Primary Outcomes

Description: The PTSD Checklist for DSM 5 is a self-reported rating scale where an individual rates the severity of each symptom of PTSD on a likert scale. The ratings on individual items are summed to create a total score, which ranges from 0 to 80, with higher scores indicating more symptoms. The relationship between changes in participants' total PCL scores at different time points and prazosin exposure - and whether this relationship is moderated by baseline biomarker values - will be analyzed using a linear mixed effects model.

Measure: Change in total PTSD Checklist for DSM 5 (PCL5) score

Time: The PCL5 total score is assessed at baseline, during each stage of the study, and at the endpoint of the study. Thus, measurements will be scheduled to occur at the following time points, relative to the baseline visit: 0, 4, 8, 9-12, 16, and 20 weeks

2 Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection

The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).

NCT04365257 COVID-19 Drug: Prazosin Other: Standard of care

Primary Outcomes

Description: Number of participants in each arm who expire.

Measure: Death

Time: up to day 60

Description: Number of participants in each arm who are hospitalized and requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO.

Measure: Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO

Time: up to day 60

Description: Number of participants in each arm who are hospitalized and requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2).

Measure: Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)

Time: up to day 60

Description: Number of participants in each arm who develop grade 3 and 4 adverse events during the study period.

Measure: Cumulative incidence of grade 3 and 4 adverse events

Time: up to day 60

Description: Number of participants in each arm who develop serious adverse events during the study period.

Measure: Number of participants with serious adverse events

Time: up to day 60

Description: Number of participants in each arm who develop symptomatic hypotension (systolic blood pressure <90 mmHg) or hypotension requiring cessation of prazosin.

Measure: Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin

Time: up to day 60

Secondary Outcomes

Description: Number of participants with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.

Measure: Number of participants with laboratory abnormalities in peripheral blood

Time: up to day 60

Description: Number of days with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.

Measure: Duration of laboratory abnormalities in peripheral blood

Time: up to day 60

Description: Number of participants with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.

Measure: Number of participants with laboratory abnormalities in plasma

Time: up to day 60

Description: Number of days with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.

Measure: Duration of laboratory abnormalities in plasma

Time: up to day 60

No related HPO nodes (Using clinical trials)